丹参冻干粉剂对非ST段抬高心肌梗死病人血浆PAI-1的影响

EFFECTS OF DANSHEN FREEZE-DRIED POWDER INJECTION ON THE LEVELS OF PAI-1 ON PATIENTS WITH NON-ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION

目的观察非ST段抬高心肌梗死(NSTEMI)病人血浆组织型纤溶酶原激活物抑制物1(PAI-1)变化和丹参冻干粉剂对其影响。方法将110例病人随机分为治疗组和对照组,两组均给予西医常规治疗,治疗组加用丹参冻干粉剂。两组分别于治疗前、治疗后14d测定血浆PAI-1浓度,观察心绞痛、严重心律失常、心力衰竭的发生情况。结果治疗组和对照组治疗前PAI-1浓度接近,治疗后14d治疗组PAI-1水平低于对照组(t=2.434,P<0.05),心绞痛、严重心律失常、心力衰竭的发生率均显著低于对照组(χ2=3.891～4.385,P<0.05)。结论丹参冻干粉剂治疗NSTEMI的效果确切,并能降低心绞痛、严重心律失常、心力衰竭的发生率。

Objective To observe the changes of plasminogen activator inhibitor-1（PAI-1） in patients with non-ST-segment-elevation myocardial infarction （MI） and evaluate the efficacy of Danshen freeze-dried powder injection on it. Methods The present study included 110 MI patients who were randomly divided into treatment group and control group. Both groups were given conventional Western medicine, while those in the treatment group were given extra Danshen freeze-dried powder injection. The plasma PAI-1 levels were detected before and after 14 days of therapy. The occurrence of angina, serious cardiac arrhythmia （SCA） and cardiac failure （CF） were observed. Results Before treatment, the plasma PAI-1 levels were similar between the two groups;after 14 days of treatment, the levels of PAI-I in the treatment group were lower than that in the control （t=2. 434, P〈0.05）, and the incidence of angina, SCA and CF were also dramatically lower than that in the control （X^2 =3. 891--4. 385 ,P〈 0.05）. Conclusion The effectiveness of Danshen freeze-dried powder injection for patients with non-ST-segment-elevation MI is certain, the medicine can reduce the occurrence of angina, SCA and CF.